艾迪药业获首创证券买入评级

金融界05-15

5月15日，艾迪药业获首创证券买入评级，近一个月艾迪药业获得3份研报关注。研报预计在艾诺米替片放量带动下，2024年HIV新药有望保持逐季度环比增长态势。公司HIV新药研发稳步推进，ACC017(整合酶抑制剂)已经进入临床I期，ACC027等多个品种处于不同研发阶段，为HIV者提供全方位治疗方案。2023年公司人源蛋白业务表现良好，其中尿激酶粗品收入1.77亿元（+71.46%），主要由于来自于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2435575488?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-15 08:45","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2435575488","market":"sh","top_or_hot":-1,"title":"艾迪药业获首创证券买入评级","media":"金融界","content":"<div>\n<p>5月15日，艾迪药业获首创证券买入评级，近一个月艾迪药业获得3份研报关注。研报预计在艾诺米替片放量带动下，2024年HIV新药有望保持逐季度环比增长态势。公司HIV新药研发稳步推进，ACC017(整合酶抑制剂)已经进入临床I期，ACC027等多个品种处于不同研发阶段，为HIV者提供全方位治疗方案。2023年公司人源蛋白业务表现良好，其中尿激酶粗品收入1.77亿元（+71.46%），主要由于来自于...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405150845388b095c92&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾迪药业获首创证券买入评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾迪药业获首创证券买入评级\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-15 08:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405150845388b095c92&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月15日，艾迪药业获首创证券买入评级，近一个月艾迪药业获得3份研报关注。研报预计在艾诺米替片放量带动下，2024年HIV新药有望保持逐季度环比增长态势。公司HIV新药研发稳步推进，ACC017(整合酶抑制剂)已经进入临床I期，ACC027等多个品种处于不同研发阶段，为HIV者提供全方位治疗方案。2023年公司人源蛋白业务表现良好，其中尿激酶粗品收入1.77亿元（+71.46%），主要由于来自于...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405150845388b095c92&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688488","symbol_name":"艾迪药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405150845388b095c92&s=b","article_id":"2435575488","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405150845388b095c92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2435575488","pubTimestamp":1715733937,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月15日，艾迪药业获首创证券买入评级，近一个月艾迪药业获得3份研报关注。研报预计在艾诺米替片放量带动下，2024年HIV新药有望保持逐季度环比增长态势。2024年1季度公司人源蛋白粗品业务收入较上年同期减少3821.41万元，公司预计主要是由于客户季节性采购金额波动和尿激酶集采降价影响。公司公告拟收购南大药业31.161%股权，进一步强化产业链布局，有望增厚收益。研报认为，艾迪药业已成功地进行了销售体系的调整，进入了快速增长阶段。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"601136":"首创证券","688488":"艾迪药业"},"translate_title":"Aidi Pharmaceuticals received a buy rating from Capital Securities","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601136":1,"688488":1},"content_text":"5月15日，艾迪药业获首创证券买入评级，近一个月艾迪药业获得3份研报关注。研报预计在艾诺米替片放量带动下，2024年HIV新药有望保持逐季度环比增长态势。公司HIV新药研发稳步推进，ACC017(整合酶抑制剂)已经进入临床I期，ACC027等多个品种处于不同研发阶段，为HIV者提供全方位治疗方案。2023年公司人源蛋白业务表现良好，其中尿激酶粗品收入1.77亿元（+71.46%），主要由于来自于南大药业采购额增加。2024年1季度公司人源蛋白粗品业务收入较上年同期减少3821.41万元，公司预计主要是由于客户季节性采购金额波动和尿激酶集采降价影响。公司公告拟收购南大药业31.161%股权，进一步强化产业链布局，有望增厚收益。2024年至2026年公司营业收入分别为5.67亿元、8.17亿元和10.97亿元，增速分别为37.9%、44.0%和34.4%。研报认为，艾迪药业已成功地进行了销售体系的调整，进入了快速增长阶段。尤其是在艾诺米替片的销售上，由于积极的商业化策略与强化的销售团队建设，加上渠道下沉力度的增大，使得新增患者从2023年11月开始反弹，使用艾诺米替片的新增患者增速明显，这显示出艾诺米替片的销售带动了公司整体销售的增长。风险提示：核心产品集采降价超预期；HIV创新药放量/获批进度低于预期。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435575488"}